EFG Asset Management North America Corp. Sells 9,323 Shares of Natera, Inc. (NASDAQ:NTRA)

EFG Asset Management North America Corp. reduced its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 17.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,051 shares of the medical research company's stock after selling 9,323 shares during the period. Natera makes up 1.0% of EFG Asset Management North America Corp.'s portfolio, making the stock its 16th biggest holding. EFG Asset Management North America Corp.'s holdings in Natera were worth $6,975,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in NTRA. Cerity Partners LLC grew its holdings in shares of Natera by 27.0% in the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company's stock worth $10,936,000 after purchasing an additional 18,316 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Natera in the third quarter worth $385,000. Everence Capital Management Inc. bought a new stake in shares of Natera during the fourth quarter valued at approximately $573,000. Smartleaf Asset Management LLC raised its position in Natera by 50.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company's stock worth $104,000 after buying an additional 220 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Natera by 87.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 67,906 shares of the medical research company's stock valued at $8,621,000 after purchasing an additional 31,649 shares during the last quarter. Institutional investors own 99.90% of the company's stock.

Remove Ads

Insiders Place Their Bets

In related news, insider John Fesko sold 663 shares of the business's stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the sale, the insider now owns 156,044 shares in the company, valued at $27,739,941.88. The trade was a 0.42 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Solomon Moshkevich sold 6,000 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $143.29, for a total value of $859,740.00. Following the completion of the sale, the insider now directly owns 143,768 shares in the company, valued at $20,600,516.72. The trade was a 4.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 306,797 shares of company stock valued at $48,940,883. Company insiders own 7.60% of the company's stock.

Natera Stock Performance

NASDAQ NTRA traded down $4.36 during trading on Friday, reaching $143.94. 1,258,459 shares of the company's stock were exchanged, compared to its average volume of 1,364,577. The business has a 50 day moving average price of $159.60 and a 200-day moving average price of $150.94. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The stock has a market capitalization of $19.46 billion, a P/E ratio of -81.78 and a beta of 1.80. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. Sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on NTRA shares. JPMorgan Chase & Co. lifted their price target on Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th. BTIG Research reaffirmed a "buy" rating on shares of Natera in a report on Friday, February 28th. Canaccord Genuity Group reiterated a "buy" rating and set a $180.00 price target on shares of Natera in a research report on Wednesday, February 26th. The Goldman Sachs Group raised their price target on shares of Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. Finally, Sanford C. Bernstein raised their target price on Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research note on Friday, January 10th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.